These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27750228)

  • 21. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
    Zappulo E; Scotto R; Buonomo AR; Maraolo AE; Pinchera B; Gentile I
    Expert Opin Pharmacother; 2020 Feb; 21(3):261-273. PubMed ID: 31914336
    [No Abstract]   [Full Text] [Related]  

  • 22. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Hepatol Int; 2016 Mar; 10(2):258-66. PubMed ID: 26542068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.
    Kanda T; Yasui S; Nakamura M; Suzuki E; Arai M; Haga Y; Sasaki R; Wu S; Nakamoto S; Imazeki F; Yokosuka O
    Int J Med Sci; 2016; 13(6):418-23. PubMed ID: 27279790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
    Signorovitch JE; Betts KA; Song Y; Sorg RA; Li J; Behl AS; Kalsekar A
    J Comp Eff Res; 2015 Nov; 4(6):593-605. PubMed ID: 26159375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: The first case report.
    Kamada T; Furuta K; Tomioka H
    Respir Investig; 2016 May; 54(3):207-10. PubMed ID: 27108017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
    Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; Hézode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD
    JAMA; 2015 May; 313(17):1736-44. PubMed ID: 25942724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
    Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
    Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
    Morisawa N; Koshima Y; Satoh JI; Maruyama Y; Kuriyama S; Yokoo T; Amemiya M
    Clin Exp Nephrol; 2017 Oct; 21(5):818-824. PubMed ID: 27771774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
    Nakamura Y; Imamura M; Kawakami Y; Teraoka Y; Daijo K; Honda F; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Chayama K
    J Med Virol; 2017 Apr; 89(4):665-671. PubMed ID: 27602542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
    Jensen D; Sherman KE; Hézode C; Pol S; Zeuzem S; de Ledinghen V; Tran A; Elkhashab M; Younes ZH; Kugelmas M; Mauss S; Everson G; Luketic V; Vierling J; Serfaty L; Brunetto M; Heo J; Bernstein D; McPhee F; Hennicken D; Mendez P; Hughes E; Noviello S;
    J Hepatol; 2015 Jul; 63(1):30-7. PubMed ID: 25703086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.
    Toyoda H; Kumada T; Tada T; Shimada N; Takaguchi K; Senoh T; Tsuji K; Tachi Y; Hiraoka A; Ishikawa T; Shima T; Okanoue T
    J Hepatol; 2017 Mar; 66(3):521-527. PubMed ID: 27890790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hirooka Y; Toyoda H; Kumada T; Hattori M; Katano Y; Goto H
    J Viral Hepat; 2018 Dec; 25(12):1446-1451. PubMed ID: 29993164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
    Lau G; Benhamou Y; Chen G; Li J; Shao Q; Ji D; Li F; Li B; Liu J; Hou J; Sun J; Wang C; Chen J; Wu V; Wong A; Wong CL; Tsang ST; Wang Y; Bassit L; Tao S; Jiang Y; Hsiao HM; Ke R; Perelson AS; Schinazi RF
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):97-104. PubMed ID: 27917405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
    Kato K; Shimada N; Atsukawa M; Abe H; Itokawa N; Matsumoto Y; Agata R; Tsubota A
    PLoS One; 2019; 14(7):e0219022. PubMed ID: 31291311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
    Nagaoki Y; Imamura M; Aikata H; Daijo K; Teraoka Y; Honda F; Nakamura Y; Hatooka M; Morio R; Morio K; Kan H; Fujino H; Kobayashi T; Masaki K; Ono A; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Hayes CN; Miki D; Ochi H; Chayama K
    PLoS One; 2017; 12(8):e0182710. PubMed ID: 28797106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
    Koshino K; Ushigome H; Masuda K; Matsuyama T; Harada S; Nakamura T; Nobori S; Iida T; Yoshimura N
    Transplant Proc; 2017 Jun; 49(5):1053-1055. PubMed ID: 28583525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.
    Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2017 Nov; 32(11):1879-1886. PubMed ID: 28258705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.
    Itakura J; Kurosaki M; Hasebe C; Osaki Y; Joko K; Yagisawa H; Sakita S; Okushin H; Satou T; Hisai H; Abe T; Tsuji K; Tamada T; Kobashi H; Mitsuda A; Ide Y; Ogawa C; Tsuruta S; Takaguchi K; Murakawa M; Asahina Y; Enomoto N; Izumi N
    PLoS One; 2016; 11(10):e0165339. PubMed ID: 27776192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
    Hassanein T; Sims KD; Bennett M; Gitlin N; Lawitz E; Nguyen T; Webster L; Younossi Z; Schwartz H; Thuluvath PJ; Zhou H; Rege B; McPhee F; Zhou N; Wind-Rotolo M; Chung E; Griffies A; Grasela DM; Gardiner DF
    J Hepatol; 2015 May; 62(5):1204-6. PubMed ID: 25559328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.